ArticleFrontiers in pharmacology2021
Dihydroartemisinin Alleviates Imiquimod-Induced Psoriasis-like Skin Lesion in Mice Involving Modulation of IL-23/Th17 Axis.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Mechanism of Artemisia annua active component quercetin in treating psoriasis by regulating ferroptosis.Scientific reports · 2026Article
- Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway.Molecules (Basel, Switzerland) · 2026Article
- Potential Cosmetic Applications of Dihydroartemisinin.Molecules (Basel, Switzerland) · 2026Article
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Pharmaceutics · 2025Review
- Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis.Phytotherapy research : PTR · 2025Article
- Liposomes-in-Gel as the Docetaxel Delivery for the Effective Treatment of Psoriasis by Inhibiting the Proliferation of Blood Vessels.Gels (Basel, Switzerland) · 2025Article
- Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells.Frontiers in immunology · 2025Review
- Dihydroartemisinin suppresses the tumorigenesis of esophageal carcinoma by elevating DAB2IP expression in a NFIC-dependent manner.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Effects of natural products on skin inflammation caused by abnormal hormones secreted by the adrenal gland.Frontiers in pharmacology · 2023Review
- Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.Frontiers in pharmacology · 2022Review
- Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.